<DOC>
	<DOCNO>NCT00560638</DOCNO>
	<brief_summary>This single-center , randomize , double-masked , placebo-controlled , parallel-group , 4-visit , CAE ( Controlled Adverse Environment ) study last approximately 4 week . Subjects randomize receive loteprednol etabonate ophthalmic suspension , 0.5 % placebo ( vehicle loteprednol etabonate ophthalmic suspension , 0.5 % ) instruct dose bilaterally either TID QID accord randomization .</brief_summary>
	<brief_title>Loteprednol Etabonate Opthalmic Suspension Treatment Dry Eye</brief_title>
	<detailed_description />
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Loteprednol Etabonate</mesh_term>
	<criteria>least 18 year age old able willing follow instruction , include participation study assessment able present require study visit duration study If female childbearing potential , pregnant , nursing , plan pregnancy . Women childbearing potential require negative urine pregnancy test prescreen visit agree use acceptable method mechanical hormonal contraceptive duration study diagnosis dry eye history intermittent regular artificial tear use within past 3 month best correct visual acuity ( BCVA ) +0.7 good assess Early Treatment Diabetic Retinopathy Study ( ETDRS ) scale one eye fluorescein stain score ≥ 1+ least one region least one eye Visit 1 CAE exposure Visits 2 3 OR fluorescein stain score ≥ 1+ least one region least one eye Visit 1 CAE exposure Visits 2 3 conjunctival redness score ≥ 1.5+ Visit 1 CAE exposure Visits 2 3 least one eye Demonstrated response expose CAE Visits 2 3 clinically significant blepharitis Meibomian Gland Dysfunction ( MGD ) lid margin inflammation , particularly systemic topical medication currently use treat diagnosis diagnose ongoing ocular infection ( bacterial , viral , fungal ) , active ocular inflammation ( e.g . follicular conjunctivitis ) , preauricular lymphadenopathy , particularly systemic topical medication currently use treat diagnosis Reported ocular discomfort score 4+ eye time 0 CAE exposure Visits 2 3 Wore contact lens refuse remove duration study previous laser situ keratomileusis ( LASIK ) surgery currently take topical ophthalmic prescription ( include medication glaucoma ) overthecounter ( OTC ) solution , artificial tear , gel scrub could discontinue medication duration study presently take medication know cause ocular dry stable dose least 30 day currently take oral antihistamine could discontinue study systemic disease , uncontrolled medical condition opinion investigator could interfere study measurement subject compliance receive another experimental drug device within 30 day prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
</DOC>